Large, Multi-Center, Multi-Society Study of Impella-supported Patients Finds 30-day AMI Cardiogenic Shock Survival of 81%
Results of a three-year, investigator-led study of all Impella-supported patients treated at 109 hospitals in Japan (n=1,344) show 30-day survival rates of 81% for AMI cardiogenic shock (AMICS) patients. The study is an update to a 2020 interim analysis and was presented at the 2022 Transcatheter Cardiovascular Therapeutics (TCT) conference taking place in Boston.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220919005279/en/
Caption: The investigator-led Inova, NCSI and J-PVAD studies all demonstrate an improvement from the historical AMI cardiogenic shock survival rate of approximately 50% when patients are treated with best practices including Impella. (Graphic: Business Wire)
The analysis examined 293 consecutive Impella-supported AMICS patients in the J-PVAD Registry, a registry conducted by 10 Japanese professional societies, including the Japanese Circulation Society (JCS). Results demonstrated 81% survival at 30 days. Historical cardiogenic shock survival rates without Impella are approximately 50%.
“The results of this study demonstrate that when Impella is used and best practices are followed, it is possible to achieve heart recovery and greater than 80% survival rates for patients with AMI cardiogenic shock,” said lead investigator Junya Ako, MD, an interventional cardiologist and chair of the department of cardiovascular medicine at Kitasato University Hospital in Kanagawa.
These results are consistent with other published investigator-led studies, such as the National Cardiogenic Shock Initiative Study (NCSI) and the Inova study by Tehrani et al., that have demonstrated significant increases in survival with the use of Impella and best practices such as placing Impella prior to percutaneous coronary intervention (PCI) (see figure 1).
J-PVAD data is independently monitored and shared with the Japan Pharmaceuticals and Medical Devices Agency (PMDA).
ABOUT IMPELLA HEART PUMPS
Impella 2.5, Impella CP®, Impella CP with SmartAssist, Impella 5.0®, Impella LD®, and Impella 5.5® with SmartAssist® are U.S. FDA approved to treat heart attack or cardiomyopathy patients in cardiogenic shock and have the unique ability to enable native heart recovery, allowing patients to return home with their own heart.
ABOUT ABIOMED
Based in Danvers, Massachusetts, USA, Abiomed (ABMD), is a leading provider of medical technology that provides circulatory support and oxygenation. Our products are designed to enable the heart to rest by improving blood flow and/or provide sufficient oxygenation to those in respiratory failure. For additional information, please visit: http://www.abiomed.com.
FORWARD-LOOKING STATEMENTS
Any forward-looking statements are subject to risks and uncertainties such as those described in Abiomed's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220919005279/en/
Contact information
For further information:
Media:
Jenny Leary
Associate Director, U.S. Communications
+1 (978) 882-8491
jleary@abiomed.com
Investor:
Todd Trapp
Executive Vice President and Chief Financial Officer
+1 (978) 646-1680
ttrapp@abiomed.com
About Business Wire
Business Wire(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Eaton Receives 2024 Automotive News PACEpilot Recognition for Its 4-Speed Electrified Vehicle Transmission6.5.2024 12:30:00 CEST | Press release
Intelligent power management company Eaton’s heavy-duty 4-speed electrified vehicle (EV) transmission was named a 2024 Automotive News PACEpilot Innovation to Watch at an awards ceremony on April 29. The recognition acknowledges post-pilot, pre-commercial innovations in the automotive and future mobility space. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240506431002/en/ Members of Eaton’s heavy-duty 4-speed electrified vehicle (EV) transmission team are, left to right, Scott Adams, Julie Marshaus, Justin Hopkins and Mark Kramer. (Photo: Business Wire) Eaton’s EV transmission provides superior performance on grades and acceleration for electric commercial vehicles while offering more flexible gear ratios compared to competitive technologies. The compact 4-speed transmission for heavy-duty applications is designed to improve system efficiency, enabling longer vehicle range and battery life. “We are honored to be chosen by
Ex- DocuSign, Oracle Leader Appointed to 6sense Senior Vice President of GTM International6.5.2024 10:00:00 CEST | Press release
6sense®, the leading platform to revolutionize the way B2B organizations create, manage, and convert pipeline to revenue, today announced the recent appointment of Andy Champion as Senior Vice President of GTM International. Champion’s impressive background brings over three decades of highly relevant experience to the organization which includes sales and marketing expertise at high growth, globally focused, private and public companies. “Andy’s track record of scaling organizations, both in headcount and revenue, will be instrumental in our global growth plans,” said Mark Ebert, SVP of Sales at 6sense. "But he also carries with him a unique ability to foster and develop both a fun and high-performing team culture. With a new London office space opening soon, I am incredibly excited for this next chapter for 6sense." The announcement highlights 6sense’s growing influence in the B2B sales and marketing landscape, with continued expansion efforts into new geographies and verticals servi
Kindeva Drug Delivery Invests in Second Manufacturing Line for Greener Inhalers at UK Manufacturing Site6.5.2024 09:00:00 CEST | Press release
Kindeva Drug Delivery (Kindeva), a global leader in drug-device combination products, today announced its investment in a second manufacturing line for the production of pressurized metered-dose inhaler (pMDI) products containing low-GWP (Global Warming Potential) propellants in its Loughborough, U.K., facility. This new line will be capable of handling both HFA-152a and HFO-1234ze propellants — that have a GWP of 90% and 99.9% lower than the industry standard HFA-134a, respectively — and is anticipated to be operational in 2026. Kindeva’s first pMDI manufacturing line, which was announced in 2022, is in its installation phase and will be completed later in 2024. Milton Boyer, Kindeva’s CEO said: “This investment will bring to the market one of the first large-volume commercial green propellant lines to the contract manufacturing market capable of supplying up to 50 million pMDI units per year. This second investment in low-GWP GMP manufacturing capacity further underscores Kindeva’s c
INRED and SES to Provide High-Throughput Connectivity Across Colombia’s Amazonas6.5.2024 08:50:00 CEST | Press release
Following a series of successful collaborations to close the digital divide, Colombian local connectivity service provider INRED and SES will deliver high-throughput connectivity services via SES’s Medium Earth Orbit (MEO) satellites to more than 500 homes, schools, government entities, and thousands of habitants in the department of Amazonas, both companies announced today. With the aim of supporting the Colombian government’s efforts to connect remote and hard-to-reach locations under the Amazonas Digital initiative, INRED is leveraging SES’s MEO satellites to connect the city of Leticia and other rural areas in Amazonas. SES’s MEO satellites, which orbit at 8,000 km above the Earth’s surface, will play a major role in complementing the government’s digital inclusion initiatives to deliver connectivity to even the most hard-to-reach regions in the country, ensuring people and businesses in these areas have equal access to social and economic opportunities. “Having a long-term partner
Xylem Unveils 'Reuse Brew'6.5.2024 08:00:00 CEST | Press release
In an innovative move to tackle Europe's escalating water scarcity, global water technology leader Xylem (NYSE: XYL), today announced the launch of Reuse Brew. This unique Bavarian beer, crafted from high-quality treated wastewater, marks a significant advancement in water recycling technologies and offers a sustainable solution to the increasing challenges posed by climate change. The development of Reuse Brew is the culmination of a partnership between the Chair of Brewery and Beverage Technology at Technical University of Munich (TUM), the Chair of Urban Water Systems Engineering at TUM, the city of Weissenburg in Bavaria, and Xylem. This collaboration showcases the transformative potential of advanced water treatment technologies in producing a palatable beer, promoting sustainable water management practices across Europe. "Reuse Brew is not merely an exceptional beer; it exemplifies the vast capabilities of water recycling in combating the pressing issue of water scarcity," said R